OptiBiotix Health Plc

Equities

OPTI

GB00BP0RTP38

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:11 2024-04-26 am EDT			5-day change	1st Jan Change
17.75 ^GBX	0.00%		-1.39%	-33.64%

Mar. 25	OptiBiotix Health raises GBP1.4 million to invest in "driving sales"	AN
Mar. 25	OptiBiotix Health Raises GBP1.4 Million via Share Placing, Subscription	MT

OptiBiotix names Croda's Graham Myers as finance director

December 04, 2023 at 07:24 am EST

OptiBiotix Health PLC - York, England-based life sciences company - Appoints Graham Myers as finance director, effective as of December 1, 2023. Says that Myers' appointment to this part-time role will see him work closely with the OptiBiotix team to support its focus on "driving each business unit and the group to profitability". Myers is currently chair of Croda Pension Trustees Ltd, the sole trustee of Croda International PLC's GBP800 million UK pension scheme.

Current stock price: 25.86 pence, down 1.5% in London on Monday

12-month change: up 64%

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	CRODA INTERNATIONAL PLC	4,703 GBX	+1.16%	-3.55%	8.18B
	OPTIBIOTIX HEALTH PLC	17.75 GBX	0.00%	-1.39%	21.65M

Latest news about OptiBiotix Health Plc

OptiBiotix Health raises GBP1.4 million to invest in "driving sales"	Mar. 25	AN
OptiBiotix Health Raises GBP1.4 Million via Share Placing, Subscription	Mar. 25	MT
EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal	Mar. 13	AN
OptiBiotix Health plc Signs Partnership Agreement with Dr Morepen Ltd	Mar. 13	CI
OptiBiotix products return to sales growth as pipeline strong	Feb. 27	AN
OptiBiotix in discussions for launch of SweetBiotix	Jan. 30	AN
OptiBiotix Health to Launch Sports Nutrition Product in Europe	Jan. 15	MT
OptiBiotix's LeanBiome to be launched under MuscleTech	Jan. 15	AN
OptiBiotix Health PlcAnnounces Launch of LeanBiome in Muscletech	Jan. 15	CI
OptiBiotix names Croda's Graham Myers as finance director	Dec. 04	AN
UK's Optibiotix Health Appoints Finance Director	Dec. 04	MT
Optibiotix Health plc Appoints Graham Myers as Finance Director	Dec. 04	CI
Scancell trial progresses; OptiBiotix inks new deal	Nov. 28	AN
Optibiotix Health plc Signs an Agreement with Ravenswood Ingredients Pty Ltd ("Ravenswood") for the Distribution of Slimbiome®In Australia and New Zealand	Nov. 28	CI
EARNINGS AND TRADING: Victorian Plumbing profit up; Duke revenue dips	Nov. 22	AN
OptiBiotix says market still "volatile" but partner sales improving	Nov. 01	AN
OptiBiotix Health Expands Network in US, Asia	Nov. 01	MT
OptiBiotix Health Secures License Deal for Tata Chemicals' Fossence; Shares Jump	23-10-23	MT
OptiBiotix adds Tata Chemicals ingredient to obesity product in India	23-10-23	AN
EARNINGS: Safestyle suffers amid "difficult" trading conditions	23-09-27	AN
Earnings Flash (OPTI.L) OPTIBIOTIX HEALTH Posts H1 Revenue GBP351,000	23-09-27	MT
Earnings Flash (OPTI.L) OPTIBIOTIX HEALTH Reports H1 Loss GBX-2.09	23-09-27	MT
OptiBiotix Health Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-27	CI
OptiBiotix Health to Launch Three Products in FY24; Shares Jump 18%	23-09-22	MT
FTSE 100 picks up on hopes BoE rates have peaked	23-09-22	AN

Chart OptiBiotix Health Plc

Duration

Period

More charts

Company Profile

OptiBiotix Health Plc is a United Kingdom-based life sciences company. The Company is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. Its technology platforms include OptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. The OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiome, SlimBiome Medical and WellBiome.

Sector

Biotechnology & Medical Research

Calendar

2024-06-25 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OPTIBIOTIX HEALTH PLC	-33.64%	21.65M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs